CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

ACHIEVE LIFE SCIENCES, INC.

ACHV
$807MSmall Cap

Next catalyst

No upcoming catalyst in our data

No upcoming FDA decision, filing or trial readout is on file for ACHV. That does not mean none is planned.

Get an email about ACHV's next catalysts

Track ACHIEVE LIFE SCIENCES (ACHV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

1 upcoming event in our data (earnings).See the timeline

Catalyst Timeline

1 upcoming, 2 past

Earnings

QUIT Earnings Report

November 2026~

Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.20 | FQ end Sep/2026 | Call: tbd

Market Overview

Stock performance and key metrics

NASDAQIn Vitro & In Vivo Diagnostic SubstancesπŸ‡ΊπŸ‡ΈNorth AmericaSEATTLE

Frequently asked questions

What is in ACHIEVE LIFE SCIENCES, INC.'s drug pipeline?β†’

CatalystAlert tracks 12 drug candidates in ACHIEVE LIFE SCIENCES, INC.'s (ACHV) pipeline across Phase 3, Phase 2. Its lead program is cabazitaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is ACHIEVE LIFE SCIENCES, INC.'s next FDA catalyst?β†’

CatalystAlert tracks every upcoming catalyst for ACHIEVE LIFE SCIENCES, INC. (ACHV) β€” PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β€” each confidence-rated as confirmed, estimated or AI-detected.

How do I track ACHV biotech catalysts?β†’

Add ACHV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ACHIEVE LIFE SCIENCES, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply